Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Mark David Orland

Mark David Orland

Internal medicine physician, Taussig Cancer Institute, Cleveland Clinic

Appears in 1 story

Notable Quotes

Patients taking GLP-1s were significantly less likely to develop metastatic cancer, said Orland in the ASCO press briefing.

Stories

GLP-1 weight-loss drugs linked to slower cancer progression

New Capabilities

Lead author presenting the study at ASCO 2026

A study of more than 12,000 patients found that those taking GLP-1 weight-loss drugs were 38% to 50% less likely to progress to stage IV cancer in four obesity-linked cancers. Cleveland Clinic researchers matched GLP-1 users — on drugs like Ozempic, Wegovy, and Mounjaro — against patients taking older diabetes pills.

Updated 16 hours ago